Titel

Sarilumab COVID-19

Kurzzusammenfassung

Primary Objectives:

Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19 Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19

Zentren/Kontakt:

Bonn

Essen

Köln

Münster, Germany

Details

 

Stand: 05.05.2020, Quelle: www.clinicaltrials.gov

Menü